A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).

CONCLUSIONS: Talazoparib exhibited promising antitumor activity in patients with aBC and germline BRCA mutation. PMID: 30563931 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30563931?dopt=Abstract

Source: Clinical Cancer Research - December 18, 2018 Category: Cancer & Oncology Authors: Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME Tags: Clin Cancer Res Source Type: research